THERION BIOLOGICS AIDS VACCINE TBC-3B ENTERS PHASE I

Executive Summary

THERION BIOLOGICS AIDS VACCINE TBC-3B ENTERS PHASE I clinical trials March 1 under the auspices of the National Institute of Allergy and Infectious Diseases' AIDS Vaccine Evaluation Group (AVEG), Cambridge, Mass.-based Therion Biologics announced Feb. 22. The study will evaluate the safety of TBC-3B and its ability to elicit HIV-specific immune responses. Preclinical trials of TBC-3B "have demonstrated the safety of the vaccine and its ability to elicit HIV-specific antibody and cell-mediated responses," Therion President and CEO Dennis Panicall said. The studies were conducted in primates.